Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler

a randomized open-label study

David Price, Anne Robertson, Kevin Bullen, Cynthia Rand, Rob Horne, Heribert Staudinger

Research output: Contribution to journalArticle

80 Citations (Scopus)
4 Downloads (Pure)

Abstract

Background
Poor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily administration.

Methods
This was a 12-week open-label study designed to mimic an actual clinical setting in patients =12 years old with mild-to-moderate persistent asthma. Patients were randomized to receive MF-DPI 400 µg once-daily in the evening or MF-DPI 200 µg twice-daily. Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses. Self-reports were also used to determine adherence. Health-related quality of life, healthcare resource utilization, and days missed from work or school were also reported.

Results
1233 patients were randomized. The mean adherence rates, as measured by the automatic dose counter, were significantly better (P < 0.001) with MF-DPI 400 µg once-daily in the evening (93.3%) than with MF-DPI 200 µg twice-daily (89.5%). Mean adherence rates based on self-reports were also significantly better (P < 0.001) with MF-DPI 400 µg QD PM (97.2%) than with MF-DPI 200 µg twice-daily (95.3%). Adherence rates were lower in adolescents (12-17 years old). Health-related quality of life improved by 20% in patients using MF-DPI once-daily in the evening and by 14% in patients using MF-DPI twice-daily. Very few (<8%) patients missed work/school.

Conclusion
Mean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen.

This trial was completed prior to the ISMJE requirements for trial registration.
Original languageEnglish
Article number1
Number of pages9
JournalBMC Pulmonary Medicine
Volume10
DOIs
Publication statusPublished - 5 Jan 2010

Fingerprint

Mometasone Furoate
Dry Powder Inhalers
Self Report
Asthma
Quality of Life
Quality of Health Care

Keywords

  • administration, inhalation
  • adolescent
  • adult
  • aged
  • anti-inflammatory agents
  • asthma
  • child
  • female
  • humans
  • male
  • medication adherence
  • middle aged
  • powders
  • pregnadienediols
  • treatment outcome
  • young adult

Cite this

Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler : a randomized open-label study. / Price, David; Robertson, Anne; Bullen, Kevin; Rand, Cynthia; Horne, Rob; Staudinger, Heribert.

In: BMC Pulmonary Medicine, Vol. 10, 1, 05.01.2010.

Research output: Contribution to journalArticle

@article{65d76b1353e14cad92e936aebe0e9225,
title = "Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study",
abstract = "BackgroundPoor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily administration. MethodsThis was a 12-week open-label study designed to mimic an actual clinical setting in patients =12 years old with mild-to-moderate persistent asthma. Patients were randomized to receive MF-DPI 400 µg once-daily in the evening or MF-DPI 200 µg twice-daily. Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses. Self-reports were also used to determine adherence. Health-related quality of life, healthcare resource utilization, and days missed from work or school were also reported. Results1233 patients were randomized. The mean adherence rates, as measured by the automatic dose counter, were significantly better (P < 0.001) with MF-DPI 400 µg once-daily in the evening (93.3{\%}) than with MF-DPI 200 µg twice-daily (89.5{\%}). Mean adherence rates based on self-reports were also significantly better (P < 0.001) with MF-DPI 400 µg QD PM (97.2{\%}) than with MF-DPI 200 µg twice-daily (95.3{\%}). Adherence rates were lower in adolescents (12-17 years old). Health-related quality of life improved by 20{\%} in patients using MF-DPI once-daily in the evening and by 14{\%} in patients using MF-DPI twice-daily. Very few (<8{\%}) patients missed work/school. ConclusionMean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen. This trial was completed prior to the ISMJE requirements for trial registration.",
keywords = "administration, inhalation, adolescent, adult, aged, anti-inflammatory agents, asthma, child, female, humans, male, medication adherence, middle aged, powders, pregnadienediols, treatment outcome, young adult",
author = "David Price and Anne Robertson and Kevin Bullen and Cynthia Rand and Rob Horne and Heribert Staudinger",
year = "2010",
month = "1",
day = "5",
doi = "10.1186/1471-2466-10-1",
language = "English",
volume = "10",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler

T2 - a randomized open-label study

AU - Price, David

AU - Robertson, Anne

AU - Bullen, Kevin

AU - Rand, Cynthia

AU - Horne, Rob

AU - Staudinger, Heribert

PY - 2010/1/5

Y1 - 2010/1/5

N2 - BackgroundPoor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily administration. MethodsThis was a 12-week open-label study designed to mimic an actual clinical setting in patients =12 years old with mild-to-moderate persistent asthma. Patients were randomized to receive MF-DPI 400 µg once-daily in the evening or MF-DPI 200 µg twice-daily. Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses. Self-reports were also used to determine adherence. Health-related quality of life, healthcare resource utilization, and days missed from work or school were also reported. Results1233 patients were randomized. The mean adherence rates, as measured by the automatic dose counter, were significantly better (P < 0.001) with MF-DPI 400 µg once-daily in the evening (93.3%) than with MF-DPI 200 µg twice-daily (89.5%). Mean adherence rates based on self-reports were also significantly better (P < 0.001) with MF-DPI 400 µg QD PM (97.2%) than with MF-DPI 200 µg twice-daily (95.3%). Adherence rates were lower in adolescents (12-17 years old). Health-related quality of life improved by 20% in patients using MF-DPI once-daily in the evening and by 14% in patients using MF-DPI twice-daily. Very few (<8%) patients missed work/school. ConclusionMean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen. This trial was completed prior to the ISMJE requirements for trial registration.

AB - BackgroundPoor adherence with prescribed asthma medication is a major barrier to positive treatment outcomes. This study was designed to determine the effect of a once-daily administration of mometasone furoate administered via a dry powder inhaler (MF-DPI) on treatment adherence compared with a twice-daily administration. MethodsThis was a 12-week open-label study designed to mimic an actual clinical setting in patients =12 years old with mild-to-moderate persistent asthma. Patients were randomized to receive MF-DPI 400 µg once-daily in the evening or MF-DPI 200 µg twice-daily. Adherence was assessed primarily using the number of actual administered doses reported from the device counter divided by the number of scheduled doses. Self-reports were also used to determine adherence. Health-related quality of life, healthcare resource utilization, and days missed from work or school were also reported. Results1233 patients were randomized. The mean adherence rates, as measured by the automatic dose counter, were significantly better (P < 0.001) with MF-DPI 400 µg once-daily in the evening (93.3%) than with MF-DPI 200 µg twice-daily (89.5%). Mean adherence rates based on self-reports were also significantly better (P < 0.001) with MF-DPI 400 µg QD PM (97.2%) than with MF-DPI 200 µg twice-daily (95.3%). Adherence rates were lower in adolescents (12-17 years old). Health-related quality of life improved by 20% in patients using MF-DPI once-daily in the evening and by 14% in patients using MF-DPI twice-daily. Very few (<8%) patients missed work/school. ConclusionMean adherence rates were greater with a once-daily dosing regimen of MF-DPI than with a twice-daily dosing regimen. This trial was completed prior to the ISMJE requirements for trial registration.

KW - administration, inhalation

KW - adolescent

KW - adult

KW - aged

KW - anti-inflammatory agents

KW - asthma

KW - child

KW - female

KW - humans

KW - male

KW - medication adherence

KW - middle aged

KW - powders

KW - pregnadienediols

KW - treatment outcome

KW - young adult

U2 - 10.1186/1471-2466-10-1

DO - 10.1186/1471-2466-10-1

M3 - Article

VL - 10

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

M1 - 1

ER -